找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Asthma: Targeted Biological Therapies; Girolamo Pelaia,Alessandro Vatrella,Rosario Masell Book 2017 Springer International Publishing Swit

[復(fù)制鏈接]
樓主: 突然
21#
發(fā)表于 2025-3-25 05:28:04 | 只看該作者
22#
發(fā)表于 2025-3-25 08:36:46 | 只看該作者
Conclusions and Future Perspectives,rapies, many of which are undergoing advanced stages of clinical investigation, will probably lead in the next future to the introduction in real life of several other biologics indicated for asthma treatment [7–11].
23#
發(fā)表于 2025-3-25 12:07:51 | 只看該作者
https://doi.org/10.1007/978-3-8348-9214-0 different responses to pharmacological therapies [5, 6]. The majority of asthmatic patients can achieve a good control of their symptoms using standard treatments including inhaled corticosteroids and bronchodilators such as β.-adrenergic agonists, as well as oral leukotriene inhibitors [7, 8].
24#
發(fā)表于 2025-3-25 18:17:28 | 只看該作者
https://doi.org/10.1007/978-3-658-30557-4 this key immunological discovery into the approval of the anti-IgE antibody omalizumab for the treatment of severe allergic asthma [7]. Indeed, omalizumab has been the first and for a long time the only biologic drug available in clinical practice for add-on therapy of uncontrolled asthma [8].
25#
發(fā)表于 2025-3-25 22:15:23 | 只看該作者
Wilfried Pla?mann,Detlef Schulzeroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma [8]. Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
26#
發(fā)表于 2025-3-26 00:52:45 | 只看該作者
27#
發(fā)表于 2025-3-26 08:20:12 | 只看該作者
28#
發(fā)表于 2025-3-26 09:47:47 | 只看該作者
IL-5-Targeted Antibodies,eroids, some subgroups of asthmatic subjects display persistent bronchial and/or blood eosinophilia, associated with an inadequate control of asthma [8]. Therefore, these patients can potentially benefit from additional therapies based on the use of biologic drugs targeting IL-5.
29#
發(fā)表于 2025-3-26 14:31:16 | 只看該作者
30#
發(fā)表于 2025-3-26 19:00:20 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-11-1 04:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
乐山市| 高邑县| 衡阳县| 乐业县| 武功县| 呈贡县| 株洲市| 彩票| 鹿泉市| 中山市| 侯马市| 南宁市| 行唐县| 金湖县| 台安县| 沙坪坝区| 桦甸市| 西和县| 县级市| 宁河县| 河南省| 旺苍县| 运城市| 宜阳县| 威海市| 永州市| 蓝田县| 济阳县| 海南省| 惠来县| 老河口市| 资中县| 湖北省| 通城县| 南溪县| 简阳市| 镇远县| 广汉市| 博兴县| 界首市| 兰西县|